Bisecting N-Acetylglucosamine on EGFR Inhibits Malignant Phenotype of Breast Cancer via Down-Regulation of EGFR/Erk Signaling

Lanming Cheng†, Lin Cao†, Yurong Wu, Wenjie Xie, Jiaqi Li, Feng Guan and Zengqi Tan*

Shaanxi Provincial Key Laboratory of Biotechnology, Joint International Research Laboratory of Glycobiology and Medicinal Chemistry, College of Life Science, Northwest University, Xi’an, China

Glycosylation, the most prevalent and diverse post-translational modification of protein, plays crucial biological roles in many physiological and pathological events. Alteration of N-glycan has been detected during breast cancer progression. Among the specific N-glycan structures, bisecting N-Acetylglucosamine (GlcNAc) is a β1,4-linked GlcNAc attached to the core β-mannose residue, and is catalyzed by glycosyltransferase MGAT3. Bisecting GlcNAc levels were commonly dysregulated in different types of cancer. In this study, we utilized mass spectrometry and lectin microarray analysis to investigate aberrant N-glycans in breast cancer cells. Our data showed the decreased levels of bisecting GlcNAc and down-regulated expression of MGAT3 in breast cancer cells than normal epithelial cells. Using PHA-E (a plant lectin recognizing and combining bisecting GlcNAc) based enrichment coupled with nanoLC-MS/MS, we analyzed the glycoproteins bearing bisecting GlcNAc in various breast cancer cells. Among the differentially expressed glycoproteins, levels of bisecting GlcNAc on EGFR were significantly decreased in breast cancer cells, confirmed by immunostaining and immunoprecipitation. We overexpressed MGAT3 in breast cancer MDA-MB-231 cells, and overexpression of MGAT3 significantly enhanced the bisecting N-GlcNAc on EGFR and suppressed the EGFR/Erk signaling, which further resulted in the reduction of migratory ability, cell proliferation, and clonal formation. Taken together, we conclude that bisecting N-GlcNAc on EGFR inhibits malignant phenotype of breast cancer via down-regulation of EGFR/Erk signaling.

Keywords: MGAT3, bisecting GlcNAc, glycopeptide, breast cancer, EGFR, EGFR/Erk signaling

INTRODUCTION

Breast cancer (BCa) is one of the most common cancers and associated with high mortality rates in women (1, 2). BCa detected in early stages is treatable, and the 5-year survival rate approaches 100% for the patients diagnosed at stage I, but decreases to 26% for patients diagnosed at stage IV (3). Thus, blood biomarkers of BCa for early detection is widely studied for improvement of prognosis and survival rate. Some blood-borne tumor markers were widely used for screening,
monitoring, and prognosis of BCa patients, for example, carbohydrate antigen 15-3 (CA15-3) (4, 5) and carcinoembryonic antigen (CEA) (6). Notably, numerous studies focused on relevant dysregulated glycosylation in the development and progression of BCa (7, 8).

Glycosylation is a template-free enzymatic process that adds monosaccharides to biomolecules such as carbohydrates, lipids, and proteins by glycosidic linkages to form glycoconjugates. Glycosylation play essential role in biological processes including cell-cell interaction (9), cancer metastasis (10), cell growth (11), cell adhesion (12), and host-virus interaction (13), etc. Alterations of glycosylation and glycogenes are closely associated with many disease progressions or identified as potential biomarkers for certain cancers (14, 15).

Not surprised, aberrant glycosylation has been implicated in BCa. Globo H and sialyl-Tn, which are highly expressed on BCa cells, are two typical cancer-associated carbohydrate antigens, and are good candidates for high-sensitivity diagnostics and cancer vaccine development (16–18). Recent studies have documented that elevated levels of sialylation, sLex epitopes, and fucosylation of N-glycan were detected in serum of BCa patients (19, 20). Significant higher levels of bi-, tri-, and tetra-antennary glycans with sLex epitopes were detected from sera of BCa patients with circulating tumor cells (CTCs) ≥5/7.5 mL compared to patients with CTCs <5/7.5 mL (21). Gangliotetraosylceramide (GG4) and its gene β3GalT4 were downregulated in transforming growth factor-β1 (TGFβ1) induced epithelial-mesenchymal transition (EMT) of NMuMG cells (22, 23). Also, we previously observed decreased levels of bisecting N-acetylgalcosamine (GlcNAc) and its glycosyltransferase N-acetylglucosaminyltransferase III (GlcNAcT-III, also termed as MGAT3) expression in TGFβ- and hypoxia- induced EMT process (24, 25).

Bisecting GlcNAc is a GlcNAc attached in a β1,4 linkage to the core β-mannose residue catalyzed by MGAT3. The presence of bisecting GlcNAc inhibits trimming by α-mannosidase II, thereby generating hybrid structures, and also prevents the actions of GlcNAcT-II, GlcNAcT-IV, and GlcNAcT-V to process and elongate N-glycan chains. Bisecting GlcNAc levels were commonly dysregulated in cancers. For examples, bisecting GlcNAc on membrane proteins were differentially expressed in colorectal cancer cells (26). Bisecting GlcNAc structures were identified in serous and endometrioid ovarian cancer tissues, but not found in control non-malignant samples (27). Bisecting GlcNAc on E-cadherin could prolong its turnover on cell surface without affecting its expression, stabilize the E-cadherin-catenin complex, and inhibit β-catenin translocation from plasma membrane into the cytoplasm and nucleus (25). Although the bisecting GlcNAc are bound on various proteins, the systemic study on the identification of glycoproteins bearing bisecting GlcNAc and exploration of the functions of bisecting GlcNAc is not well-elucidated.

In this study, we investigated the levels of bisecting GlcNAc in various breast cells using high-throughput techniques (MALDI-TOF/TOF-MS and lectin microarray), identified the target proteins bearing bisecting GlcNAc using lectin PHA-E enrichment coupled with NanoLC-MS/MS analysis, and explored the effects of bisecting GlcNAc on target protein.

**MATERIALS AND METHODS**

**Cell Culture**

Human mammary epithelial cell line (MCF10A) and human BCa cell lines (MCF7, MDA-MB-231, and SK-BR-3) were purchased from the Cell Bank at the Chinese Academic of Science (Shanghai, China). BCa cells were cultured in DMEM supplemented with 10% FBS (Biological Industries; Kibbutz Beit Haemek, Israel), 100 UI/mL penicillin, and 100 µg/mL streptomycin (Gibco; Carlsbad, CA, USA). MCF10A cells were grown in DMEM/F12 supplemented with 100 ng/mL cholera enterotoxin, 10 µg/mL insulin, 0.5 µg/mL hydrocortisol, 20 ng/mL EGF, 5% horse serum, 100 UI/mL penicillin, and 100 µg/mL streptomycin at 37°C in 5% CO2.

**Total Protein Extraction**

Total protein extraction was performed as described previously (24). Briefly, cells were detached, rinsed, and lysed with RIPA buffer (50 mM Tris, pH 7.2, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 10 mM MgCl2, 5% glycerol) supplemented with protease inhibitor, and centrifuged. The supernatant was collected and stored at –80°C. Protein content was determined by BCA assay (Beyotime Institute of Biotechnology; Haimen, China).

**Western Blot**

Western blot was performed as described previously. In brief, the total protein (30 µg) were separated SDS-PAGE. The gels were transferred to PVDF membranes. The membranes were blocked with 5% BSA, and incubated with primary antibodies against MGAT3 (1:500; ab135514; Abcam, Cambridge, MA, UK), GAPDH (1:10,000; G9545; Sigma-Aldrich, St. Louis, MO, USA), ERK (1:1,000; 4696; Cell Signaling Technology, Beverly, MA, USA), p-ERK (1:1,000; 4370; Cell Signaling Technology), AKT (1:1,000; 4685; Cell Signaling Technology), p-AKT (Ser473; 1:2,000; 4606; Cell Signaling Technology), p-EGFR (Y1173; 1:1,000; 4407; Cell Signaling Technology), p-EGFR (Y1086; 1:1,000; 3777; Cell Signaling Technology) and EGFR (1:1,000; 4267; Cell Signaling Technology) overnight at 4°C, and incubated with HRP conjugated secondary antibody.

**MALDI-TOF/TOF-MS of N-glycans From Breast Cell Lines**

MALDI-TOF/TOF-MS of N-glycans were performed as described previously (24). Briefly, cell lysates were denatured with UREA, DTT and IAM, and digested with PNGase F (New England BioLabs; Ipswich, MA, USA), lyophilized, and subjected to MALDI-TOF-MS of N-glycans were performed as described previously (24). Briefly, cell lysates were denatured with UREA, DTT and IAM, and digested with PNGase F (New England BioLabs; Ipswich, MA, USA), lyophilized, and subjected to MALDI-TOF/TOF-MS (UltraflexXtreme, Bruker Daltonics; Bremen, Germany) analysis in positive-ion mode. Mass signals were analyzed and annotated with GlycoWorkbench software (http://code.google.com/p/
glycoworkbench) (28). Relative proportion was calculated by adding the relative intensity of the same type of N-glycans.

### Lectin Microarray Analysis

Lectin microarray was performed and analyzed as described previously (29). In brief, 37 lectins from Vector Laboratories (Burlingame, CA, USA), Sigma-Aldrich (St. Louis, MO, USA), or Merck (Darmstadt, Germany) were immobilized onto epoxysilane-coated solid support. Sample proteins were labeled with Cy3 (GE Healthcare; Buckinghamshire, UK) and subjected to the lectin microarray. The microarrays were scanned with a GenePix 4000B confocal scanner (Axon Instruments; Union City, CA, USA). The data was analyzed as previously described (29).

### Lectin Staining/Immunofluorescence

Lectin staining was performed as described previously (29). In brief, cells cultured in confocal dishes, were rinsed with ice-cold 1 × PBS, fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, blocked with 5% BSA. For lectin staining, cells were incubated with FITC-labeled PHA-E (FL-1121; Vector Laboratories, Burlingame, CA, USA) and SNA (FL-1301; Vector Laboratories). For immunofluorescence, cells were incubated with primary antibodies against EGFR (D38B1; Cell Signaling Technology; Danvers, MA, USA) and fluorescence-labeled secondary antibody. Cells were stained with DAPI, rinsed with PBS, and photographed with confocal microscope (Olympus FV1000; Olympus; Tokyo, Japan).

### Protein Digestion

Protein digestion was performed as described previously (30). In brief, proteins were extracted with 8 M UREA/1 M NH4HCO3 from above cells and sonicated thoroughly. Total proteins (2 mg) were reduced by 5 mM DTT for 1 h at 37°C, alkylated by addition of 15 mM IAM for 30 min in the dark at RT, and incubated with sequencing grade trypsin (Promega; Madison, WI, USA; protein: enzyme, 50:1, w/w) at 37°C overnight. The digested peptides were acidified with 10% trifluoroacetic acid to pH <3 and desalted with Oasis HLB SPE column (Waters; Milford, MA, USA).

### Glycoprotein Enrichment by Lectin PHA-E

Total peptides (150 µg) were incubated with agarose bound PHA-E in binding buffer (20 mM Tris-HCl containing 100 mM NaCl, 5 mM MnCl2, and 5 mM CaCl2) overnight at 4°C. The mixture was centrifuged for 1 min at 2,500 g and supernatant was removed. The precipitates were rinsed four times with binding buffer by vortex for 10 s. The sample was boiled for 10 min, and supernatant was collected after centrifugation. Glycopeptides were digested with PNGase F and lyophilized.

### NanoLC-MS/MS Analysis

The enriched glycopeptides were analyzed by an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific). Peptides were separated on an Easy-nLC 1200 system with a 20 cm C18 separating column. Mobile phase flow rate was 300 nL/min and consisted of 0.5% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). The gradient profile was set as follows: 0–12% B for 10 min, 12–33% B for 130 min, 33–100% B for 15 min, and 100% B for 10 min. The spray voltage was set at 2,000 V. Orbitrap spectra (AGC 1 × 106) was collected from 300 to 2,000 m/z at a resolution of 60 K using an isolation window of 0.7 m/z. A dynamic exclusion time of 10 s was used. All LC-MS/MS data was searched against reviewed Homo sapiens reference proteome databases (version 201502) using Maxquant 1.5.1.12 (Cox, Mann, 2008). The sequences and masses of peptides were extracted from the results with FDR <1%.

### Immunoprecipitation

Cell lysates (500 µg) were incubated with 1 µg primary antibody against EGFR (D38B1) for 2 h at 4°C, and 20 µL protein A/G-agarose (Santa Cruz Biotechnology; Santa Cruz, CA, USA) was added. The mixture was incubated with rotation overnight at 4°C, rinsed with PBS, denatured with loading buffer, and subjected to SDS-PAGE and western blot.

### Wound Closure Assay

Cells were plated in 6-well plates to achieve almost 100% confluence. Cells were scratched with a 100 μL pipette tips, rinsed with PBS, incubated in DMEM supplemented with 10% FBS and 5 μg/mL mitomycin C (Sigma-Aldrich) for 24 h. Cell migration between the scratch areas was monitored at 0 and 24 h, using optical microscope. Migration distance was measured with Image Pro Plus 6.0 (Media Cybemetics, MD, USA).

### Proliferation Assay

Cell proliferation assay was performed using iClick Edu Andy Fluor 647 Flow Cytometry Assay Kit (GeneCopoeia; CA, USA) according to the instruction manual. Briefly, control and MGAT3 over-expressed MDA-MB-231 cells were treated with 40 μM Edu for 6 h. Cells were fixed at appropriated fixation buffer for 15 min at room temperature. After staining and washing with PBS, cells were detected with flow cytometry.

For CCK8 assay, cells were plated in 96-well plate, and incubated with CCK8 (Beyotime Institute of Biotechnology) solution for 4 h. The absorbance in each well was quantified at 450 nm using a microplate reader.

### Clonal Formation Assay

Colony formation was performed as described previously (31). Cells were plated in a 6-cm dish, and cultured for 1–2 weeks until small colonies were clearly observed. Cells were rinsed with PBS, fixed with 4% paraformaldehyde, stained with crystal violet solution, and photographed. Acetic acid solution (10%) was added to dissolve the crystal violet, and absorption at 595 nm was measured.

### Invasion Assay

Invasion assay was performed using cell culture inserts (pore size 8 μm; Corning; New York, USA) as per manufacturer’s instructions. 2 × 104 cells in serum-free medium were starved for 24 h, inoculated in upper chamber coated with Matrigel (Corning), and complete medium was added to bottom chamber. After 24 h culture, cells migrated across the membrane were stained with 0.1% crystal violet, and photographed under microscope (magnification 100×).
Flow Cytometry
Cells coated on 24-well plates were detached with trypsin, rinsed with 1 × PBS, blocked with 5% BSA, incubated with FITC-conjugated PHA-E (FL-1121) and SNA (FL-1301) at 4°C for 2 h. Signals from cells were detected by flow cytometry (ACEA NovoCyte; Hangzhou, China), with data acquisition and analysis by the NovoExpress™ software (ACEA bioscience).

Overexpression of MGAT3
MGAT3 overexpression was performed as previously described (32). Briefly, MGAT3 was cloned into pLVX-AcGFP1-N1 (Takara; Shiga, Japan) lentiviral vector. Lentivirus was packaged in HEK293T cells and collected from medium supernatant. MDA-MB-231 cells were established by infecting lentivirus into cells, and pooled stable transected cells were selected by adding puromycin. The experiment was performed in duplicate, and the two stable transfected cells were termed as MGAT3-1 and MGAT3-2. Unless otherwise indicated, MGAT3-1 cell line was used for functional study of MGAT3.

Knockdown of MGAT3
Lentiviral shRNA vector is constructed using pLVX-shRNA2-puro (Takara), and packed into HEK293T cells together with pMD2.G and psPAX2. Virus particles were collected, and used to infect MDA-MB-231 cells. Transfected MDA-MB-231 cells were selected by puromycin. Target sequences are listed below. Target1: 5′-TGTATGGGCTGGACGGCAT-3′; Target2: 5′-CCCAACTTCAGACAGTATGA-3′.

Lung Colonization Studies
Six- to eight-week-old female Balb/c nu/nu mice were injected with 2 × 10⁶ cancer cells which labeled with luciferase via tail vein. Bioluminescence was determined 6–8 week after injection. Mice were euthanized 8 week after injection, and lungs were fixed, sectioned, and stained with hematoxylin and eosin (H&E) for quantification of metastatic tumor burden.

Statistical Analysis
All experiments were reproduced at least three times. All data are represented as mean ± standard deviation (s.d.). Two-tailed Student’s t-test was used for comparison of data sets between two groups, and differences with p < 0.05 were considered statistically significant. Statistical analyses were performed using GraphPad Prism V. 7.0 software program. Notations in figures: *p < 0.05; **p < 0.01; ***p < 0.001.

RESULT
N-glycan Profiles of Normal and BCa Cells
In previous study, we found the down-regulated expression of bisecting GlcNAc N-glycans in EMT process (24). However, it is not unequivocal if the suppressed bisecting GlcNAc levels is common in BCa cells. We profiled the N-glycans in human mammary epithelial cell line (MCF10A) and human BCa cell lines (MCF7, MDA-MB-231, and SK-BR-3) by MALDI-TOF/TOF-MS analysis. Representative MS spectra of N-glycans were annotated using GlycoWorkbench software (Figure 1). A total of 56 distinct N-glycan structures were identified in the four breast cell lines. MCF10A, MCF7, SK-BR-3, and MDA-MB-231 cells showed 35, 36, 21, and 17 distinct m/z N-glycans, respectively. Nine N-glycan structures were presented in both normal and BCa cells but with different intensities. Six of N-glycan structures, only detected in MCF10A, were annotated as bisecting GlcNAc (Supplementary Table 1).
Relative proportions of different types of N-glycans were calculated and shown in Table 1. We observed that relative proportion of high mannose type of N-glycans were elevated, and which of multi-antennary, and fucosylation were suppressed in three BCa cells comparing to MCF10A cells. Relative proportion of total bisecting GlcNAc in BCa cells were significantly decreased in BCa cells, as shown the Venn diagram (Figure 4B). These glycopeptides between normal and BCa cells were further comparatively quantified. A number of 150 differentially expressed glycopeptides (fold change $>1.5$ or $<0.67$, $p < 0.05$) from 112 glycoproteins were identified, and visualized as a “heatmap” (Figure 4C, Supplementary Table 2). These results indicated that there were characteristic differences in the glycopeptides with bisecting GlcNAc among normal and BCa cells.

Next, gene ontology (GO) terms enrichment analysis of differentially expressed glycoproteins were performed by the Cytoscape plugin BiNGO (Figure 4D). Notably, glycoproteins with bisecting GlcNAc structures were annotated as residing in vacuole, lysosome, and lytic vacuole. Regarding biological processes, identified glycoproteins were mainly involved in catabolic process, regulation of cell-cell adhesion and vacuole organization. With regard to molecular functions, target glycoproteins were enriched in EGF-activated receptor activity, hydrolase activity, and signaling receptor binding. Most significantly enriched KEGG pathway was adhesion junction, cell adhesion molecules and lysosome.

The relationship between the differentially expressed glycoproteins were revealed by the string database (https://string-db.org/). Interactions between them were shown using Cytoscape (Figure 4E). We noticed that HSPA8, EGFR, LAMP1, CD63, and LAMP2 represent main hubs with highest degree scores. As EGFR plays an essential role during BCa progression, EGFR-associated subnetwork was extracted, as shown in Supplementary Figure 1. Down-regulated glycoproteins bearing bisecting GlcNAc, including CTSB, CD63, EPCAM, integrin β4, and TACSTD2 showed clear interactions with EGFR.

The Confirmation of Bisecting GlcNAc Modification on EGFR
To confirm the differential abundance and cellular location of glycoproteins with bisecting GlcNAc detected in BCa cells by mass spectrometry, immunofluorescence assay was performed. The results showed that EGFR and bisecting GlcNAc were distributed and co-localized on cell membrane (Figure 5A). Lower expression of EGFR was detected in whole cell lysates of MDA-MB-231 BCa cells induced by EGFR expression knockdown.
compared to which of MCF10A cells (input of Figure 5B). Immunoprecipitation showed significantly decreased levels of bisecting GlcNAc on similar levels of immunoprecipitated EGFR (Figure 5B).

**The Effect of Bisecting GlcNAc on EGFR Function**

To investigate the functional role of bisecting GlcNAc on target glycoproteins in BCa cells. MGAT3 gene was cloned
### Table 2: Glycopattern changes between normal and BCa cells as determined by lectin microarray analysis.

| Lectin  | Binding structure                      | MCF7/MCF10A | MDA-MB-231/3 MCF10A | SK-BR-3/ MCF10A | Ratio          |
|---------|----------------------------------------|-------------|---------------------|-----------------|---------------|
| AAL     | Terminal Fucα,1,6GlcNAc                | 2.7gNS      | 2.15*               | 1.27NS          | 0.54**        |
| ACA     | Galβ1-3GalNAcα-Ser/Thr                | 3.07***     | 3.00**              | 2.60***         |               |
| BPL     | Galβ1-3GalNAc                         | 1.69**      | 3.78NS              | 4.03            |               |
| ConA    | Branched and terminal Man              | 0.43**      | 0.32*               | 0.59**          |               |
| DBA     | GalNAcα-Ser/Thr                       | 1.03NS      | 1.02NS              | 1.40**          |               |
| DSA     | GlcNAc                                | 0.73NS      | 1.45**              | 0.08***         |               |
| ECA     | Galβ1-1,4GlcNAc                       | 0.31***     | 0.44***             | 0.45**          |               |
| EEL     | Galα1-3(Fucα1-2)Gal                   | 1.07*       | 0.52NS              | 0.61*           |               |
| GNA     | Terminal α,1,3 Man                     | 1.27***     | 0.38NS              | 0.88NS          |               |
| GSL-I   | αGalNAc, αGalNAc                      | 3.96*       | 2.34***             | 2.53*           |               |
| GSL-II  | GlcNAc                                | 1.69***     | 3.64*               | 4.78***         |               |
| HHL     | Non-substituted α,1,6 Man              | 0.89**      | 0.48NS              | 0.52**          |               |
| Jaccini | Galβ1-3GalNAcα-Ser/Thr (T)            | 0.53NS      | 0.97***             | 0.61**          |               |
| LCA     | Fucα1-6GlcNAc (core)                  | 0.53***     | 0.22***             | 0.43**          |               |
| LEL     | Poly-LacNAc                           | 0.79NS      | 0.73NS              | 0.66NS          |               |
| LTL     | αLeα, Lex                             | 0.57NS      | 0.88*               | 1.25NS          |               |
| MAL-I   | Galβ1-1,4GlcNAc                       | 1.51***     | 0.68*               | 1.43*           |               |

(Continued)

### Table 2: Continued

| Lectin  | Binding structure                      | MCF7/MCF10A | MDA-MB-231/3 MCF10A | SK-BR-3/ MCF10A | Ratio          |
|---------|----------------------------------------|-------------|---------------------|-----------------|---------------|
| MAL-II  | Siaα2-3Galβ1-4GlcNAc                  | 0.54**      | 0.21*               | 0.31**          |               |
| MPL     | αGalNAc                               | 2.75NS      | 1.28*               | 0.83NS          |               |
| NPA     | Non-substituted α-1,6Man              | 1.09***     | 2.96NS              | 3.31**          |               |
| PHA-E   | Bisecting GlcNAc and bi-antennary N-glycans | 0.68** | 0.42*               | 0.51**          |               |
| PHA-E+L | Bisecting GlcNAc and bi-antennary N-glycans | 0.46* | 0.66***             | 0.81*           |               |
| PSA     | Fucα-N-acetylchitobiose-Man            | 2.15*       | 3.93**              | 7.88***         |               |
| PTL-I   | αGalNAc and Gal                       | 0.99***     | 2.18NS              | 1.85**          |               |
| PTL-II  | Gal                                   | 0.89**      | 1.32NS              | 1.42*           |               |
| PSR     | GalNAc                                | 0.33***     | 0.32***             | 0.60*           |               |
| RCA120  | Gal, GalNAc                           | 1.42**      | 0.29*               | 0.57**          |               |
| SBA     | Terminal GalNAc (especially GalNAcα1-3Gal) | 0.91NS | 0.62NS              | 1.42*           |               |
| SJA     | Terminal GalNAc and GalNAcα1-3Gal     | 0.11*       | 2.01*               | 2.12*           |               |
| SNA     | Sia2-6Galβ1-4GlcNAc                   | 7.04***     | 2.69***             | 2.65**          |               |
| STL     | (GlcNAc)n                             | 1.78**      | 5.03*               | 3.29*           |               |
| UEA-I   | Fucα1-2Galβ1-4GlcNAc                  | 2.45*       | 3.42***             | 5.13***         |               |
| WA      | GalNAc                                | 0.82*       | 0.64NS              | 0.94NS          |               |
| WFA     | GalNAcα/β1-3/6Gal                     | 0.28*       | 1.48***             | 1.40*           |               |
| WGA     | Multivalent Sia                       | 0.70**      | 0.36NS              | 0.60*           |               |

NS, not significant; *p < 0.05; **p < 0.01; and ***p < 0.001.
FIGURE 3 | Altered levels of glycan pattern in BC cells. Levels of bisecting GlcNAc (A) and α2-6 linked sialic acids (B) by flow cytometry. Levels of bisecting GlcNAc (C) and α2-6 linked sialic acids (D) by lectin staining. (E) Levels of bisecting GlcNAc and α2-6 linked sialic acids by lectin blot.

and introduced into MDA-MB-231 cells (two transfectants termed MGAT3-1 and MGAT3-2). The enhanced MGAT3 expression and bisecting GlcNAc levels were validated by western blot (Figure 6A). Scratch wound assay revealed that migratory ability of MDA-MB-231 cells was decreased by introduction of bisecting GlcNAc (Figure 6B). Compared to the vector control, MGAT3 transfectant presented the suppressed proliferation by Edu incorporation assay and CCK8 assay (Figures 6C,D), decreased clonal formation (Figure 6E), and invasion ability (Figure 6F). Immunoprecipitation with antibody against EGFR showed significantly increased levels of bisecting GlcNAc on equal amounts of immunoprecipitated EGFR (Figure 6G), which also demonstrated EGFR as the target glycoprotein of bisecting GlcNAc. Notably, MGAT3 overexpression did not affect the total expression of EGFR, but decreased the levels of EGFR phosphorylation at Y1068 and Y1173 residues (Figure 6H). Furthermore, levels of ERK phosphorylation was decreased at T202/Y204 residues, and AKT phosphorylation was not changed (Figure 6H). MGAT3 was also introduced into another breast cancer cell line BT549 (Supplementary Figure 2A), and overexpression of MGAT3 resulted in decreased proliferation, migratory ability and clonal formation (Supplementary Figures 2B–D). We further silenced MGAT3 expression in MDA-MB-231 cells, shown as Supplementary Figure 2E. Cell proliferation, migratory ability and clonal formation were increased in MGAT3-shRNA transfectant (Supplementary Figures 2F–H). To further evaluate the effect of bisecting GlcNAc on migration and invasion in vivo, MGAT3-overexpressing MDA-MB-231 and parental cells were injected into nude mice via the tail vein. As expected, incidence, numbers, and areas of lung metastasis nodules was significantly decreased introduction of bisecting GlcNAc (Figures 6I–K). The results showed that bisecting GlcNAc could retard the cancerous phenotype of BCa cells by suppressing EGFR/ERK signaling.
FIGURE 4 | Identification of glycoproteins bearing bisecting GlcNAc. (A) Workflow of glycoproteomic analysis by combination of PHA-E enrichment and LC-MS/MS. (B) Venn diagram of numbers of identified glycoproteins from MCF10A, MCF7, MDA-MB-231, and SK-BR-3 cells. (C) Heatmap of significantly regulated glycopeptides with bisecting GlcNAc. Each colored cell on the map corresponds to a concentration value of the glycopeptide with identified bisecting GlcNAc glycosylation site. (D) Functional classification of differentially regulated glycoproteins bearing bisecting GlcNAc using Cytoscape plugin BiNGO based on universal GO and KEGG annotation terms. (E) Functional network analysis of differentially regulated glycoproteins using Cytoscape software. Red and blue nodes represented up- and down-regulated glycoproteins. Nodes with more interaction neighbors were displayed in larger size, and edges with larger combined scores were displayed in large size.
DISCUSSION

Glycosylation is implicated in protein folding and stability, cell-cell interaction, angiogenesis, immune modulation, and cell signaling in normal and malignant cells (33). Aberrant glycosylation is an established hallmark of BCa such as CA 16-3, carcinoembryonic antigen (CEA). In our previous study, bisecting GlcNAc levels and MGAT3 expression were decreased in TGFβ-induced EMT of NMuMG cells and hypoxia-induced EMT of MCF7 and MDA-MB-231 cells. In this study, we used an integrated strategy (MALDI-TOF/TOF-MS in combination with lectin microarray) to profile N-glycan alterations in BCa cells comparing to normal cells. Suppressed levels of multi-antennary, bisecting GlcNAc and fucosylation, and elevated levels of high mannose type N-glycans were observed in BCa cells. Theoretically, in the process of N-glycan biosynthesis, bisecting GlcNAc inhibits the catalytic activity of FUT8 and GlcNAcT-V (34). Therefore, reduced levels of bisecting GlcNAc may elevate the levels of multi-antennary structures and fucosylation.

The discrepancy may result from preferential action FUT8 and GlcNAcT-V prior to MGAT3. The elevation of high-mannose N-glycans (Man9, m/z 1905.630) were observed in BCa patient serum (35), consistent with increased levels of high-mannose N-glycans in BCA cells in our study, which indicated an incomplete glycosylation process that transform high-mannose N-glycans to complex and hybrid N-glycans. Core fucosylation (catalyzed by FUT8) and β1,6-branching GlcNAc (catalyzed by GlcNAcT-V) have been reported to be enhanced in various cancers (36–38). Core fucosylation plays a key role in the discovery of cancer biomarkers, and core fucosylated α-fetoprotein (AFP) is a well-known tumor marker for hepatocarcinoma (39). β1,6-branching GlcNAc regulates cell surface residency of target proteins, and facilitates the cellular signaling and malignant phenotypes in cancer cells (40). The presence of bisecting GlcNAc may affect the catalytic activity of other glycosyltransferase, thereby resulting in the inhibition of malignant phenotypes.

Modification of bisecting GlcNAc was reported to result in a modulation in biological function of target glycoproteins. To profile the target glycoproteins with bisecting GlcNAc, lectin PHA-E enrichment coupled with nanoLC-MS/MS was performed, and 271 target glycoproteins were identified in normal and BCa cells. Among the identified glycoproteins, EGFR and integrin were previously documented to be decorated with bisecting GlcNAc (11, 41, 42). In PC2 neuronal cells, MGAT3 overexpression contributed to an increase level of bisecting GlcNAc on EGFR, resulting in a significant decrease in EGF binding, EGFR autophosphorylation, ERK activation (43). The introduction of the bisecting GlcNAc to integrin α5 inhibited cell spreading and migration on fibronectin (41). At the molecular level, bisecting GlcNAc might suppress the addition of polyLacNAc on target proteins including EGFR, laminin-332 and integrin. In this case, galectins cannot form the signaling platform, inhibiting both cellular signaling and cell migration (40). In present study, revealed by the protein-protein interaction (PPI) network analysis, EGFR was defined as one of the hub genes with highest degree of connectivity, and interacted with several glycoproteins such as integrin β4 and α3. In confirmation assay, differential expression of EGFR was detected in whole cell lysates of MDA-MB-231 and MCF10A (input of Figure 5B), which was not in line with the similar levels of EGFR evaluated by immunofluorescence (Figure 5A). The discrepancy might result from the differences of the two techniques in quantification.
FIGURE 6 | Effects of bisecting GlcNAc on migration, proliferation, clonal formation, and EGFR/ERK signaling activation. (A) Expression of MGAT3 and levels of bisecting GlcNAc in control (Vector) and MGAT3-overexpression MDA-MB-231 cells (two transfectants, termed MGAT3-1 and 2). (B) Migratory ability of MGAT3 and vector transfectants assessed by wound assay. Transfectant MGAT3-1 was used for following functional assay analysis. Cell monolayers were scratched with pipette tip. Cells were washed with ice-cold PBS and photographed at 0 and 24 h (100 × magnification). *p < 0.05. Cell proliferation of MGAT3 and vector transfectants by (Continued)
Increased level of bisecting GlcNAc on EGFR lowered the molecular weight of EGFR (Figure 6G), which might result from the changes in glycosylation. Increased level of bisecting GlcNAc also suppressed the migratory ability, cell proliferation and clonal formation ability by suppressing the EGFR/Erk signaling pathway, in MGAT3-overexpressed MDA-MB-231 cells. This data confirmed the inhibitory function of bisecting GlcNAc on EGFR, consistently with other studies (11, 44, 45).

Moreover, in this study, other identified glycoproteins, including lamp1, TGFβRII, HSPA8, etc., were not reported to be decorated with bisecting GlcNAc to date. Lamp1 was a major carrier of polyLacNAc substituted β1,6 branched GlcNAc in melanoma cells. Translocation of lamp1 with polyLacNAc to the surface was closely associated with the metastatic potential (46). PolyLacNAc decoration on lamp1 provides abundant ligands (polyLacNAc) for galectin-3 distributed on the surface of vascular endothelium, facilitating lung homing (46, 47). We proposed that bisecting GlcNAc modification on lamp1 might decrease levels of polyLacNAc, and suppress interaction of lamp1 and galectin-3, and result in low metastatic potential. TGFβRI and TGFβRII were reported to be N-glycosylated. Expression of N-acetylglucosaminyltransferase V (MGAT5) enhanced the interaction of galectin-3 and TGFβRII, and delayed the removal of TGFβR by constitutive endocytosis, sensitized mouse cells to multiple cytokines (48). Similarly, bisecting GlcNAc modification might resist the activation to multiple cytokines by weakening the interaction of galectin-3 and TGFβR. Furthermore, recent study showed that bisecting GlcNAc on intact glycopeptides could be recognized by two characteristic ions at low energy HCD spectra (49). This advanced analytical strategy may help to identify more intact glycopeptides with bisecting GlcNAc in future study.

In conclusion, we found decreased levels of bisecting GlcNAc in BCa cells compared to normal breast cells by mass spectrometer and lectin microarray. Using PHA-E-based enrichment coupled with nanoLC-MS/MS, glycoproteins bearing bisecting GlcNAc were identified in various BCa cells. Among identified glycoproteins, levels of bisecting GlcNAc on EGFR were significantly decreased in BCa cells. Introduction of bisecting GlcNAc on EGFR in BCa MDA-MB-231 cells resulted in the reduction of migratory ability, cell proliferation, clonal formation, and suppression of EGFR/Erk signaling. Our study might provide potentially valuable information for BCa diagnosis and treatment.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT
The study was carried out in accordance with the recommendations of the Institutional Animal Care and Use Committee of Northwest University. The protocol was approved by the Institutional Animal Care and Use Committee of Northwest University.

AUTHOR CONTRIBUTIONS
FG and ZT conceived and initiated this project. All experiments described in this paper were performed by LCh, LCa, YW, WX, and JL, who then generated the figures and tables for the paper. LCh, LCa, and ZT wrote the first draft of the manuscript, which was then further edited by FG.

FUNDING
This study was supported by the National Science Foundation of China (Nos. 31971211 and 81802654), Natural Science Foundation of Shaanxi Province, China (2018JQ3051, 2018JM3014, and 2019JZ-22), and Youth Innovation Team of Shaanxi Universities.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.00929/full#supplementary-material

Supplementary Figure 1 | Functional network analysis of EGFR-associated subnetwork. Supplementary Figure 2 | Effects of bisecting GlcNAc on migration, proliferation, and clonal formation. Supplementary Table 1 | Proposed structures and their molecular ions in MALDI Spectra of N-glycans from normal and BCa cells. Supplementary Table 2 | Glycopeptides identified bearing bisecting GlcNAc by nanoLC-MS.
REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. (2019) 69:7–34. doi: 10.3322/caac.21551
2. Sung H, Siegel RL, Torre LA, Angwin J, Kerns KA, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. (2019) 69:88–112. doi: 10.3322/caac.21499
3. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. (2019) 69:363–85. doi: 10.3322/caac.21565
4. Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. Clin Chim Acta. (2015) 446:16–22. doi: 10.1016/j.cca.2014.11.001
5. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chim Acta. (2002) 48:1296–304. doi: 10.1016/s0007-4799(02)00288-7
6. Paolotti C, Hayes DF. Molecular testing in breast cancer. Annu Rev Med. (2014) 65:95–110. doi: 10.1146/annurev-med-070912-143853
7. Adamiczyk B, Tharmalingam T, Rudd PM. Glycans as cancer biomarkers. Biochim Biophys Acta. (2012) 1820:1347–53. doi: 10.1016/j.bbadeng.2011.12.001
8. Liu X, Nie H, Zhang Y, Yao Y, Maitikabili A, Qu Y, et al. Cell-surface-specific N-glycan profiling in breast cancer. PLoS ONE. (2013) 8:e72704. doi: 10.1371/journal.pone.0072704
9. Fernandez MM, Ferragut F, Cardenas Delgado VM, Bracalente C, Bravo AI, et al. Glycosylation-dependent binding of galectin-8 to activated leukocyte cell surface adhesion molecule (ALCAM/CD166) promotes its surface segregation on breast cancer cells. Biochim Biophys Acta. (2016) 1860:2255–68. doi: 10.1016/j.bbadeng.2016.04.019
10. Magalhaes A, Duarte HO, Reis CA. Aberrant glycosylation in cancer: a novel molecular mechanism controlling metastasis. Cancer Cell. (2017) 31:73–5. doi: 10.1016/j.ccell.2017.03.012
11. Song Y, Agliay J, Bernstein JD, Goswami S, Stanley P. The bisecting GlcNAc on N-glycans inhibits growth factor signaling and retards mammary tumor progression. Cancer Res. (2010) 70:3361–71. doi: 10.1158/0008-5472.CAN-09-2719
12. Hou S, Hang Q, Isaji T, Lu J, Fukuda T, Gu J. Importance of membrane-proximal N-glycosylation on integrin beta1 in its activation and complex formation. FASEB J. (2016) 30:4120–31. doi: 10.1096/fj.201606655R
13. Zhao D, Liang L, Wang S, Nakao T, Li Y, Liu L, et al. Glycosylation of the hemagglutinin protein of H5N1 influenza virus increases its virulence in mice by exacerbating the host immune response. J Virol. (2017) 91:e02215-16. doi: 10.1128/JVI.02215-16
14. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-potentail measurements of serum glycan profiles. Clin Chem. (2008) 54:1166–75. doi: 10.1373/clinchem.2007.087148
15. Saldova R, Reuben J, Hamid UA, Rudd P, Cristofanilli M. Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. Ann Oncol. (2011) 22:1113–9. doi: 10.1093/annonc/mdq790
16. Guan F, Handa K, Hakomori SI. Specific glycosphingolipids mediate epithelial-to-mesenchymal transition of human and mouse epithelial cell lines. Proc Natl Acad Sci USA. (2009) 106:7461–6. doi: 10.1073/pnas.0902368106
17. Guan F, Schaffer L, Handa K, Hakomori SI. Functional role of gangliotetraosylceramide in epithelial-to-mesenchymal transition process induced by hypoxya and by TGF-β. FASEB J. (2010) 24:4889–903. doi: 10.1096/fj.09-162107
18. Tan Z, Lu W, Li X, Yang G, Guo J, Yu H, et al. Altered N-glycan expression profile in epithelial-to-mesenchymal transition of MMU-MG cells revealed by an integrated strategy using mass spectrometry and glycan and lectin microarray analysis. J Proteome Res. (2014) 13:2783–95. doi: 10.1021/pr401185z
19. Xu Q, Isaji T, Lu Y, Gu W, Kondo M, Fukuda T, et al. Roles of N-acytelyglucosaminyltransferase III in epithelial-to-mesenchymal transition induced by transforming growth factor β1 (TGF-β1) in epithelial cell lines. J Biol Chem. (2012) 287:16563–74. doi: 10.1074/jbc.M111.262154
20. Sethi MK, Thaysen-Andersen M, Smith JT, Baker MS, Packer NH, Hancock WS, et al. Comparative N-glycan profiling of colorectal cancer cell lines reveals unique bisecting GlcNAc and α-2,3-linked sialic acid determinants are associated with membrane proteins of the more metastatic/aggressive cell lines. J Proteome Res. (2014) 13:277–88. doi: 10.1021/pr400861m
21. Allam H, Aoki K, Benigno BB, McDonald J, Mackintosh SG, Tiemer M, et al. Glycomic analysis of membrane glycoproteins with bisecting glycosylation from ovarian cancer tissue reveals novel structures and functions. J Proteome Res. (2015) 14:434–46. doi: 10.1021/pr501174p
22. Ceroni A, Maass K, Geyer H, Geyer R, Dell A, Haslam SM. GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. J Proteome Res. (2008) 7:1650–9. doi: 10.1021/pr0708252
23. Yu H, Zhu M, Qin Y, Zhong Y, Tan H, Wang Q, et al. Analysis of glycan-related genes expression and glycan profiles in mice with liver fibrosis. J Proteome Res. (2012) 11:5277–85. doi: 10.1021/pr300484y
24. Shah P, Wang X, Yang W, Toghi Eshghi S, Sun S, Hoti N, et al. Integrated proteomic and glycoproteomic analyses of prostate cancer cells reveal glycoprotein alteration in protein abundance and glycosylation. Mol Cell Proteomics. (2014) 15:273–63. doi: 10.1074/mcp.M115.047928
25. Yu M, Zhao Q, Shi L, Li F, Zhou Z, Yang H, et al. Cationic iridium(III) complexes for phosphorepense staining in the cytoplasm of living cells. Chem. Commun. (2008) 18:2115–7. doi: 10.1039/b809039b
26. Tan Z, Wang C, Li X, Guan F. Bisecting N-acetylgalactosamine structures inhibit hypoxya-induced epithelial-mesenchymal transition in breast cancer cells. Front. Physiol. (2018) 9:210. doi: 10.3389/fphys.2018.00210
27. Moremen KW, Tiemer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. (2012) 13:448–62. doi: 10.1038/nrm3383
28. Taniguchi N, Kizuka Y. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapies. Adv Cancer Res. (2015) 126:111–51. doi: 10.1016/bse.acr.2014.11.001
29. de Leoz ML, Young LJ, An HJ, Kronewitter SR, Kim J, Miyamoto S, et al. The ST6GalNAc-I isialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sia1yl-Tn O-glycan in human breast cancer. J Biol Chem. (2006) 281:3586–94. doi: 10.1074/jbc.M51182600
30. Wang CC, Huang YL, Ren CT, Lin CW, Hung JT, Yu JC, et al. Glycan microarray of globo H and related structures for quantitative analysis of breast cancer. Proc Natl Acad Sci USA. (2008) 105:11661–6. doi: 10.1073/pnas.0804923105
31. Abd Hamid UM, Royle L, Saldova R, Radcliffe CM, Harvey DJ, Storr SJ, et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology. (2008) 18:1105–18. doi: 10.1093/glycob/cwn995
32. Kyseslova Z, Mecchef Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, et al. Breast cancer diagnosis and prognosis through quantitative analysis of serum glycan profiles. Clin Chem. (2008) 54:1166–75. doi: 10.1373/clinchem.2007.087148
the early diagnosis of hepatocellular carcinoma. Cancer. (1988) 61:769–74. doi: 10.1002/1097-0142(19880215)61:4<769::aid-cncr2820610422>3.0.co;2-m
40. Kariya Y, Kawamura C, Tabei T, Gu J. Bisecting GlcNac residues on laminin-332 down-regulate galectin-3-dependent keratinocyte motility. J. Biol. Chem. (2010) 285:3330–40. doi: 10.1074/jbc.M109.038836
41. Isaji T, Gu J, Nishiuchi R, Zhao Y, Takahashi M, Miyoshi E, et al. Introduction of bisecting GlcNac into integrin α5β1 reduces ligand binding and down-regulates cell adhesion and cell migration. J. Biol. Chem. (2004) 279:19747–54. doi: 10.1074/jbc.M311627200
42. Sato Y, Takahashi M, Shibukawa Y, Jain SK, Hamaoka R, Miyagawa J, et al. Overexpression of N-acetylgalactosaminyltransferase III enhances the epidermal growth factor-induced phosphorylation of ERK in HeLaS3 cells by up-regulation of the internalization rate of the receptors. J Biol Chem. (2001) 276:11956–62. doi: 10.1074/jbc.M008551200
43. Gu J, Zhao Y, Isaji T, Shibukawa Y, Ihara H, Takahashi M, et al. β1,4-N-acetylgalactosaminyltransferase III down-regulates neurite outgrowth induced by co-stimulation of epidermal growth factor and integrins through the Ras/ERK signaling pathway in PC12 cells. Glycobiology. (2004) 14:177–86. doi: 10.1093/glycob/cwh016
44. Miwa HE, Song Y, Alvarez R, Cummings RD, Stanley P. The bisecting GlcNac in cell growth control and tumor progression. Glycoconjug. J. (2012) 29:609–18. doi: 10.1007/s10719-012-9357-6
45. Takahashi M, Kuroki Y, Ohtsubo K, Taniguchi N. Core fucose and bisecting GlcNac, the direct modifiers of the N-glycan core: their functions and target proteins. Carbohydr Res. (2009) 344:1387–90. doi: 10.1016/j.carres.2009.04.031
46. Krishnan V, Bane SM, Kawle PD, Naresh KN, Karraiya RD. Altered melanoma cell surface glyclosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis. (2005) 22:11–24. doi: 10.1007/s10585-005-2036-2
47. Srinivasan N, Bane SM, Ahire SD, Ingle AD, Karraiya RD. Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3. Glycoconjug J. (2009) 26:445–56. doi: 10.1007/s10719-008-9194-9
48. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. (2004) 306:120–4. doi: 10.1126/science.1102109
49. Dang L, Shen J, Zhao T, Zhao F, Jia L, Zhu B, et al. Recognition of bisecting N-glycans on intact glycopeptides by two characteristic ions in tandem mass spectra. Anal. Chem. (2019) 91:5478–82. doi: 10.1021/acs.analchem.8b05639

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Cheng, Cao, Wu, Xie, Li, Guan and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.